Sucampo Pharmaceuticals

Sucampo acquires Vtesse

Tuesday, April 4, 2017

Sucampo Pharmaceuticals, a global biopharmaceutical company, has acquired Vtesse, a privately held rare disease company, for upfront consideration of $200 million. Sucampo funded the acquisition through the issuance of 2,782,678 shares of Sucampo Class A common stock and $170 million of cash on hand; no external financing was utilized. 

[Read More]